ALXN Alexion Pharmaceuticals Inc

By Adria Calatayud

AstraZeneca PLC said Wednesday that its $39 billion acquisition of Alexion Pharmaceuticals Inc. is expected to close next week after it obtained final clearance from the U.K. Competition and Markets Authority

The antitrust watchdog earlier said it has decided not to refer the deal for an in-depth review based on the information currently available to it.

AstraZeneca said the acquisition is expected to close on July 21. It previously said the deal was expected to close in the third quarter.

The company said it will provide updated 2021 financial guidance for the combined entity in due course.

Earlier this month, the Cambridge, U.K.-based pharmaceutical company said it had received clearance from the European Union for its purchase of Alexion.

AstraZeneca in December agreed to acquire Boston-based Alexion for $39 billion in cash and stock to expand its offering of treatments for rare diseases.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

July 14, 2021 05:03 ET (09:03 GMT)

Grafico Azioni Alexion Pharmaceuticals (NASDAQ:ALXN)
Storico
Da Ott 2024 a Nov 2024

Grafico Azioni Alexion Pharmaceuticals (NASDAQ:ALXN)
Storico
Da Nov 2023 a Nov 2024